Treating prostate cancer: where do we draw the line?


The article by Drs. Lepor and Donin is a provocative look at a timely topic in urologic oncology.[1] There is little debate among experts in the field that we are overtreating prostate cancer at the current time. Studies are ongoing to evaluate active surveillance as an option for low-risk tumors, even in men with very long life expectancies. However, in… (More)


Cite this paper

@article{Ellis2014TreatingPC, title={Treating prostate cancer: where do we draw the line?}, author={W. J. Ellis}, journal={Oncology}, year={2014}, volume={28 1}, pages={29, 32} }